**FOR IMMEDIATE RELEASE**

**Biocair joins Pharma.Aero's pioneering project to elevate cell and gene therapy logistics**

[Biocair](https://www.biocair.com/), a leading specialist in cell and gene therapy logistics, is proud to announce its alliance with [Pharma.Aero](https://pharma.aero/), a global cross-industry collaboration platform. Together, they are driving transformation in the cell and gene therapy (CGT) supply chain.

Cell and gene therapies are a revolutionary way to fight disease in that they offer patients complete personalization of medicine. These time-sensitive and life-changing medicines need logistics solutions as innovative as they are.

To ensure the supply chain is consistently improving, Pharma.Aero set up the Cell and Gene Therapies Project. This is an industry-wide initiative that explores the fast-developing CGT sector and the particularities that have an impact on its logistics.

Over 50 life science logistics stakeholders and several external partners took part to enhance awareness and streamline the critical aspects of CGT shipments. Biocair is at the forefront of this project, advocating for the importance of accuracy, visibility and reliability in CGT logistics.

Christopher Good, Director of Cell & Gene Therapy Logistics at Biocair, affirms "Our mission is to ensure that the whole supply chain understands the significance of CGT logistics. These shipments are not just packages but life-saving therapies requiring the utmost care and attention."

Good continues “It’s been a privilege and necessity for us to be involved in the Pharma.Aero project. We’ve thoroughly enjoyed collaborating with other stakeholders and building new relationships that will benefit the efficiency of the supply chain. We look forward to continuing to work together to combat the industry-wide areas for improvement highlighted as a result of the project.”

The project's findings are presented in a [white paper](https://pharma.aero/wp-content/uploads/2023/02/Pharma.Aero-CGT-Project-WHITE-PAPER.pdf) that offers a detailed perspective on this emerging industry, identifying logistical challenges and highlighting some key points where the supply chain stakeholders could act. Five main actions have been developed:

* Strengthen the skills of the players in the airfreight sector, including keeping up to date with key regulatory developments as the sector continuously evolves
* Facilitate the flow of materials and substances due to the time and temperature criticality of the CGT supply chain
* Reduce time/Eliminate time loss through controlling processes and adequate training, as well as incorporating the latest technologies to improve productivity
* Identify products as specific to the CGT industry and design tailored solutions to support these
* Limit regulatory constraints and upgrade CEIV, as well as reflecting on the certifications and support required by industry

Frank Van Gelder, Secretary General of Pharma.Aero, emphasizes the organization’s dedication to exploring cell and gene therapies and their impact on logistics. “In the realm of air cargo, the development of personalized medicine products, unprecedented in their complexity, presents a unique set of challenges, necessitating careful logistics management. Our Pharma.Aero members, working collaboratively in this space, are confronting logistical demands that require meticulous monitoring, mapping, digitalization, precise timing, troubleshooting, and, ultimately, accurate delivery to the patient”, added Van Gelder.

Biocair's participation in the Pharma.Aero CGT Project aligns with the company’s mission to move science forward. They provided a specialist perspective on CGT logistics during the industry-wide webinar that informed the white paper. Experts from Biocair stressed the need for meticulous handling and proactive monitoring of these sensitive shipments as opposed to taking a reactive approach.

Learn more about Biocair’s [cell and gene supply chain service](https://www.biocair.com/solutions/cell-and-gene-supply-chain)s.

For more information on the Pharma.Aero CGT Project, please [visit here](https://pharma.aero/pharmaprojects/cell-and-gene-therapy-cgt/).

**ENDS**

**About Biocair**

Since 1986, Biocair has established a global reputation as a leading GDP logistics specialist within the pharmaceutical, biotechnology and life sciences sectors. Biocair has built up a unique, client-centric approach by employing scientists in front-line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance. Biocair focuses on providing the most comprehensive time-sensitive and temperature-controlled logistics services available whilst delivering flexible, tailored, cost-effective solutions to all its clients. It is committed to delivering complete end-to-end logistics solutions through its 24/7 operation and global network spanning across Europe, Africa, Asia and the Americas.

Biocair employs over 550 people worldwide and provides specialist logistics services to more than 160 countries through a global network of partners. Biocair’s offices are located in the UK, France, Belgium, Germany, USA, South Africa, China, Singapore and India.

In 2012 Biocair was acquired as an autonomous division by Geopost. Geopost is the largest parcel delivery network in Europe, which posted sales of €15.6 billion in 2022. Geopost is a holding company owned by Groupe La Poste.

For further information on Biocair, please visit [www.biocair.com](http://www.biocair.com).

For more information please contact:

**Allison Averitt** **Katie Ford**

Communications Specialist PR & Content Account Director

[Allison.Averitt@Biocair.com](mailto:Allison.Averitt@Biocair.com) [katie.ford@anicca.co.uk](mailto:katie.ford@anicca.co.uk)

**About Pharma.Aero**

Pharma.Aero is a leading global cross-industry collaboration platform of over 60 Life Science and MedTech manufacturers, cargo pharma-certified communities and other logistics stakeholders. Founded in 2016, our organization has matured into an industry thought leader by developing cutting-edge projects, providing expertise and insights, and addressing new trends, thus fueling the changes needed for tomorrow's Life Science and MedTech logistics’ strategies.  https://pharma.aero

Pharma.Aero is also co-founder and organizer of the annual International Pharma Logistics Masterclass. Since its first edition, in 2021, this unique program brings together industry executives, experts, policy makers and international academics for a knowledge exchange experience of immense value.

For further information on Pharma.Aero, please visit [www.pharma.aero](http://www.pharma.aero)

For more information please contact:

**Alice Iacobescu**

Communication Coordinator

[alice.iacobescu@pharma.aero](mailto:alice.iacobescu@pharma.aero?subject=Pharma.Aero%20Cell%20and%20Gene%20Therapy%20Project)